COVID-19 Infection Fatality Ratio is Close to One Percent
|
By HospiMedica International staff writers Posted on 10 Nov 2020 |
A new report reveals that the COVID-19 infection fatality ratio (IFR) is 1.15% in high-income countries, but substantially lower in low-income countries with younger populations.
Researchers at Imperial College London (Imperial; United Kingdom) screened 175 studies to update estimates of COVID-19 IFR. Based on 10 representative antibody surveys, they found that age-specific IFRs followed a log-linear pattern, with the risk of death doubling approximately every eight years of age. They estimated that overall IFR in a typical low-income country, with a population structure skewed towards younger individuals, was 0.23%. In contrast, in a typical high income country, with a greater concentration of elderly individuals, the overall IFR was 1.15%.
Age-specific IFRs increased from 0.1% for those under 40 years to greater than 5% among individuals over 80 years. When accounting for seroreversion—the waning of antibodies leading to a negative serological result-- the IFR was slightly reduced among surveys conducted several months after the first wave of the outbreak, such as in Italy. In contrast, uncertainty in test false positive rates, combined with low serological prevalence in some surveys, reconciled apparently low crude fatality ratios with the IFR in other countries. The findings were published on October 29, 2020, by the MRC Centre for Global Infectious Disease Analysis.
“Although the elderly are by far at the highest risk of dying due to COVID-19, the risk in middle age is still high. For example, we estimate that around one in 260 people aged 50-55 years die if infected,” said senior author Lucy Okell, PhD. “We calculated COVID-19 fatality largely based on the first wave of the epidemic in a number of countries, and we hope and expect to see some reduction in fatality now due to new clinical knowledge and treatment, but this remains a dangerous virus.”
“We know that antibody tests are not perfect, and there may be a considerable number of people who do not mount a detectable antibody response to SARS-CoV-2,” said study co-author Robert Verity, PhD. “However, even when this uncertainty is taken into account, we still find that COVID-19 has a high fatality rate, on the order of one percent for a typical high-income country. This risk is concentrated in older ages, with the probability of dying from COVID-19 doubling approximately every eight years.”
IFR is a key statistic for estimating disease burden, representing the proportion of deaths among all infected individuals. Previous estimates have relied on data early in the COVID-19 epidemic, or have not fully accounted for uncertainty in serological test characteristics and delays from onset of infection to seroconversion, death, and antibody waning.
Related Links:
Imperial College London
Researchers at Imperial College London (Imperial; United Kingdom) screened 175 studies to update estimates of COVID-19 IFR. Based on 10 representative antibody surveys, they found that age-specific IFRs followed a log-linear pattern, with the risk of death doubling approximately every eight years of age. They estimated that overall IFR in a typical low-income country, with a population structure skewed towards younger individuals, was 0.23%. In contrast, in a typical high income country, with a greater concentration of elderly individuals, the overall IFR was 1.15%.
Age-specific IFRs increased from 0.1% for those under 40 years to greater than 5% among individuals over 80 years. When accounting for seroreversion—the waning of antibodies leading to a negative serological result-- the IFR was slightly reduced among surveys conducted several months after the first wave of the outbreak, such as in Italy. In contrast, uncertainty in test false positive rates, combined with low serological prevalence in some surveys, reconciled apparently low crude fatality ratios with the IFR in other countries. The findings were published on October 29, 2020, by the MRC Centre for Global Infectious Disease Analysis.
“Although the elderly are by far at the highest risk of dying due to COVID-19, the risk in middle age is still high. For example, we estimate that around one in 260 people aged 50-55 years die if infected,” said senior author Lucy Okell, PhD. “We calculated COVID-19 fatality largely based on the first wave of the epidemic in a number of countries, and we hope and expect to see some reduction in fatality now due to new clinical knowledge and treatment, but this remains a dangerous virus.”
“We know that antibody tests are not perfect, and there may be a considerable number of people who do not mount a detectable antibody response to SARS-CoV-2,” said study co-author Robert Verity, PhD. “However, even when this uncertainty is taken into account, we still find that COVID-19 has a high fatality rate, on the order of one percent for a typical high-income country. This risk is concentrated in older ages, with the probability of dying from COVID-19 doubling approximately every eight years.”
IFR is a key statistic for estimating disease burden, representing the proportion of deaths among all infected individuals. Previous estimates have relied on data early in the COVID-19 epidemic, or have not fully accounted for uncertainty in serological test characteristics and delays from onset of infection to seroconversion, death, and antibody waning.
Related Links:
Imperial College London
Latest Critical Care News
- Origami Robots to Deliver Medicine Less Invasively and More Effectively
- Improved Cough-Detection Technology Aids Health Monitoring
- AI Identifies Children in ER Likely to Develop Sepsis Within 48 Hours
- New Radiofrequency Therapy Slows Glioblastoma Growth
- Battery-Free Wireless Multi-Sensing Platform Revolutionizes Pressure Injury Detection
- Multimodal AI to Revolutionize Cardiovascular Disease Diagnosis and Treatment
- AI System Reveals Hidden Diagnostic Patterns in Electronic Health Records
- Highly Sensitive On-Skin Sensing Monitor Detects Vitamin B6 and Glucose in Sweat
- Artificial Intelligence Revolutionizing Pediatric Anesthesia Management
- New Device Detects Tuberculosis DNA Directly in Exhaled Air
- New Menstrual Cup Could Detect Infections and Improve Diagnostics
- Engineered “Natural Killer” Cells Could Help Fight Cancer
- Faster Lymph Flow Predicts Better Response to Diuretics in Acute Heart Failure
- New Global Recommendations Aim to End Deaths from Postpartum Hemorrhage
- 'Flat-Line ECG' Indicates Poor Outcomes for Out-Of-Hospital Cardiac Arrest
- New Guidance to Improve Diagnosis and Management of Heart Failure During Pregnancy and Postpartum
Channels
Surgical Techniques
view channel
Novel Glue Prevents Complications After Breast Cancer Surgery
Seroma and prolonged lymphorrhea are among the most common complications following axillary lymphadenectomy in breast cancer patients. These postoperative issues can delay recovery and postpone the start... Read more
Breakthrough Brain Implant Enables Safer and More Precise Drug Delivery
Delivering medication directly to specific regions of the brain has long been a major challenge in treating neurological disorders. Current implants and infusion systems typically reach only one or two... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read moreFirst-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel
Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies
Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
B. Braun Acquires Digital Microsurgery Company True Digital Surgery
The high-end microsurgery market in neurosurgery, spine, and ENT is undergoing a significant transformation. Traditional analog microscopes are giving way to digital exoscopes, which provide improved visualization,... Read more
CMEF 2025 to Promote Holistic and High-Quality Development of Medical and Health Industry
The 92nd China International Medical Equipment Fair (CMEF 2025) Autumn Exhibition is scheduled to be held from September 26 to 29 at the China Import and Export Fair Complex (Canton Fair Complex) in Guangzhou.... Read more







